Fig. 1.

A single intravenous infusion of EGFRvIII-specific CART cells prolongs survival of tumor-bearing mice but results in recurrence demonstrating target antigen loss. (A) mCAR domains. (B) Treatment protocol schematic and Kaplan-Meier survival curves. No treatment (n = 7; MS 19 days), LD (n = 7; MS 24 days), RV-CART (n = 8; MS 19 days), LD + RV-CART (n = 8; MS 28 days). (C) Tumor samples from mice at the endpoint were collected and analyzed by FC for EGFRvIII expression. (D) Summary of FC staining for myeloid populations in samples from (C). (E) Prospective study of tumor tissues 3-day post-LD + CART i.v. infusion. Representative FC diagrams for tumor single-cell suspensions are shown. Abbreviations: CART, chimeric antigen receptor-transduced T cells; FC, flow cytometry; LD, lymphodepletion; MS, median survival.